ReviewInflammatory intestinal diseases
Emu Oil: A Potential Adjunct to Inflammatory Bowel Disease Treatment?
Review in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is a chronic lifelong condition that affects the colon to a variable extent. Current treatments for IBD include aminosalicylate-based drugs, corticosteroids, antibiotics, immunomodulators, biologics, other small-molecule drugs, and surgical intervention. Nonetheless, treatment options are variably effective, associated with serious side effects, and often leave individuals at risk of relapse. Summary: In this narrative review, we explore emu oil (EO), a naturally sourced agent, that may be utilised to broaden therapeutic options in IBD. The anti-inflammatory, antioxidant, reparative, and protective properties of EO have been attributed to its unique blend of fatty acids and non-triglyceride fraction. To date, several preclinical trials of orally administered EO have demonstrated these properties in a range of intestinal inflammatory conditions, showing reduced inflammation and mucosal damage, together enhancing intestinal healing. Key Messages: While EO remains an interesting candidate for future investigations, current knowledge is limited to animal models and its clinical relevance is yet to be defined. Well-designed clinical trials will be essential to determine the safety and efficacy of EO before it can be considered as a potential adjunct to conventional therapy for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.